Ask AI

Precision in Practice: Implementing HER2 Testing and HER2-Directed Therapy in Gynecologic Cancers

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 29, 2026

Expiration: April 28, 2027

See Activity Collection

In this on-demand webcast, an expert reviews the role of HER2 testing and HER2-directed therapies in gynecologic cancers, with a focus on endometrial, ovarian, and cervical cancers. They examine HER2 protein expression, gene amplification, and activating mutations; tumor-specific testing and scoring criteria; and factors contributing to discordant results, including tumor heterogeneity, specimen selection, and assay variability. Clinical evidence supporting HER2-directed treatment strategies is highlighted, including efficacy and safety findings from the DESTINY-PanTumor02 and STATICE trials evaluating trastuzumab deruxtecan, along with emerging data on investigational HER2-directed ADCs and ongoing clinical trials. Case-based discussions address the interpretation of HER2 results, treatment selection based on tumor histology and biomarker status, and strategies for monitoring and managing treatment-related adverse events, particularly ILD/pneumonitis.

HER2 Testing and Tx in Gynecologic Cancers

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with gynecologic cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following is the most appropriate next step to clarify HER2 status and guide treatment selection?

4.

Which of the following represents the most appropriate next treatment strategy for this patient?

5.

Which of the following represents the most appropriate next step by the multidisciplinary care team?